“…Furthermore, data from real-life settings are important also in patients affected by infections, such as patients affected by latent tuberculosis, as well as patients affected by COVID-19. [60][61][62][63][64][65][66][67][68] Indeed, these conditions may raise several safety concerns during the treatment decision progress. Hence, real-life studies may represent an important source of data to improve the decision-making progress, leading physicians to choose the best treatment for the best patient.…”
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real-life data are important to improve the dermatological decision-making process, including patients who are typically excluded from clinical trials, such as subjects suffering from several comorbidities, subjects on polypharmacy, as well as multifailure patients. Herein, we performed a comprehensive literature review about real-life data available on guselkumab, risankizumab, and tildrakizumab. Real-life data of anti-IL-23 seem to confirm the promising results of IL-23 shown by clinical trials, highlighting the efficacy and safety profiles of this new class of biologics also in clinical practice.
“…Furthermore, data from real-life settings are important also in patients affected by infections, such as patients affected by latent tuberculosis, as well as patients affected by COVID-19. [60][61][62][63][64][65][66][67][68] Indeed, these conditions may raise several safety concerns during the treatment decision progress. Hence, real-life studies may represent an important source of data to improve the decision-making progress, leading physicians to choose the best treatment for the best patient.…”
Interleukin (IL)-23 inhibitors, guselkumab, risankizumab, and tildrakizumab, represent the latest class of biologics approved for the treatment of moderate-to-severe psoriasis. Since their approval numerous real-life studies were published on anti-IL-23 use in routine clinical practice. Indeed, real-life data are important to improve the dermatological decision-making process, including patients who are typically excluded from clinical trials, such as subjects suffering from several comorbidities, subjects on polypharmacy, as well as multifailure patients. Herein, we performed a comprehensive literature review about real-life data available on guselkumab, risankizumab, and tildrakizumab. Real-life data of anti-IL-23 seem to confirm the promising results of IL-23 shown by clinical trials, highlighting the efficacy and safety profiles of this new class of biologics also in clinical practice.
“…Moreover, the effectiveness of COVID-19 vaccines in patients undergoing treatment with biologics is debated. 59,60 Bostan et al 37 (1), Nagrani et al 35 (1), Pavia et al 38 (1), Durmus et al 39 (1), Fang et al 40 (1), Krajewski et al 41 (1), Trepanowski et al 42 (1), Mieczkowska et al 43 (1), Lopez et al 44 (1), Perna et al 45 (1), Tsunoda et al 47 (1), Nia et al 48 (1), Pesqué et al 28 Lichen planus is a chronic, inflammatory, autoimmune disease with an unknown pathogenesis. 61 To date, 13 cases of new-onset cutaneous lichen planus and 3 cases of cutaneous lichen planus exacerbation have been reported.…”
Section: Resultsmentioning
confidence: 99%
“…Moreover, the effectiveness of COVID-19 vaccines in patients undergoing treatment with biologics is debated. 59 , 60 Figure 1 Cutaneous reactions investigated and number of cases. Figure 2 Percentage of vaccine types investigated that cause cutaneous reactions.…”
The outbreak of coronavirus disease 2019 represented a new worldwide challenge, strongly impacting on the global economy, overall health and lifestyle. Since then, several strategies have been adopted to contain the widespread of infection. Among these, vaccination is currently the most important measure to fight against the pandemic. However, several concerns such as slower-than-hoped-for rollout, the hurried approval with limited data, the mechanism of action (in particular mRNA-based), and the uncertain duration of protection they afforded were initially raised. Moreover, even if cutaneous reactions have been rarely reported in clinical trials, global mass vaccination showed several dermatologic reactions not initially recognized, leaving dermatologists to decide how to diagnose and treat them. In this scenario, dermatologists should be ready to promptly recognize these clinical manifestations. Thus, the aim of this manuscript is to review current literature on cutaneous reactions following COVID-19 vaccination, particularly inflammatory dermatological diseases, in order to help clinicians to better understand these dermatological conditions and to provide an extensive overview of all the vaccine-related skin manifestations.
“… 5 Several concerns on the safety of biologic treatment have been raised and several strategies have been adopted to increase compliance with treatment and reduce vaccine hesitancy among these patients. 6 , 7 Currently, data on the immune response to COVID‐19 vaccination in patients with psoriasis receiving biologics are scant and often conflicting. 3 , 4 …”
Section: Tablementioning
confidence: 99%
“…5 Several concerns on the safety of biologic treatment have been raised and several strategies have been adopted to increase compliance with treatment and reduce vaccine hesitancy among these patients. 6,7 Currently, data on the immune response to COVID-19 vaccination in patients with psoriasis receiving biologics are scant and often conflicting. 3,4 Clinicians must keep in mind the safety and effectiveness of COVID-19 vaccination in patients undergoing biologic treatment, and also consider the risk of psoriasis worsening following the vaccine.…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
